Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on December 10, 2019. The filing addresses Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Waltham, Massachusetts.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on operational updates rather than financial performance data.
Material Changes
The primary material event reported is the announcement of plans to commence a Phase 2 expansion study of SNDX-6352, the company's anti-CSF-1R monoclonal antibody. This study targets the treatment of chronic graft versus host disease (cGVHD).
Guidance, Outlook, and Risks
- Outlook: Management plans to advance the development of SNDX-6352 for cGVHD patients through the new Phase 2 expansion study.
- Exhibits: The filing incorporates a press release (Exhibit 99.1) and a revised corporate presentation (Exhibit 99.2) containing further details on the trial update.
- Risks: The report includes standard forward-looking statement disclaimers. Actual results may differ materially from expectations due to known and unknown risks, uncertainties, and other factors affecting the development timeline and success of SNDX-6352.
Investor Verification Checklist
- Verify the specific design and enrollment criteria of the Phase 2 expansion study for SNDX-6352 in cGVHD via the attached press release.
- Review the revised corporate presentation (Exhibit 99.2) for updated timelines and strategic priorities.
- Monitor future filings for data readouts or regulatory interactions regarding the cGVHD indication.
- Check the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial figures.